FAKTOR-OPTIONSSCHEIN - ASTRAZENECA | Market Closed - Börse Stuttgart 10:09:31 2024-06-07 EDT | ||
| 10.63 EUR | 0.00% |
|
| Current month | +10.84% | ||
| 1 month | +9.47% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 10.63 | 0.00% |
| 24-06-06 | 10.63 | +2.51% |
| 24-06-05 | 10.37 | +0.19% |
| 24-06-04 | 10.35 | +2.48% |
| 24-06-03 | 10.1 | +5.32% |
Delayed Quote Börse Stuttgart
Last update June 07, 2024 at 10:09 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | MD39YW |
| ISIN | DE000MD39YW6 |
| Date issued | 2022-04-07 |
| Strike | 8,395 p |
| Maturity | Unlimited |
| Parity | 4.63 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.83 € |
|---|---|
| Lowest since issue | 4.85 € |
| Spread | 0.02 € |
| Spread % | 0.19% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
159.8
USD
Average target price
173.1
USD
Spread / Average Target
+8.38%
- Stock Market
- Certificates
- Certificat
